MaxCyte, Inc.
NASDAQMXCT reported Q1 2026 results on May 12 that cleared the revenue bar — yet the stock barely moved, closing at $0.82 and down about 2.4% on the week. That disconnect between an in-line print and a sub-$1 share price captures the central tension here: management is executing to plan, but the market is paying close to nothing for a business with a $100 million SPL milestone pipeline…
Snapshot as of 28 Jun 2026
MXCT reported Q1 2026 results on May 12 that cleared the revenue bar — yet the stock barely moved, closing at $0.82 and down about 2.4% on the week. That disconnect between an in-line print and a sub-$1 share price…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MXCT — free to start on ORTEX.
Sign up for free →Open MXCT on ORTEX